Connect Biopharma to Join Leerink Partners I&I and Metabolism Forum

Suzhou Connect Biopharmaceuticals, Ltd., a U.S.-headquartered and global clinical-stage biopharmaceutical firm, is making significant strides in the field of chronic inflammatory diseases. On July 1, 2024, the company announced that its top executives, including CEO Barry Quart, President David Szekeres, and CFO Steven Chan, will engage in one-on-one investor meetings at the Leerink Partners Inflammation and Immunology (I&I) and Metabolism Therapeutics Forum. This event is scheduled to occur on July 9-10, 2024, in Boston, MA.

Connect Biopharma, with its focus on T cell biology and drug discovery, is committed to the development of innovative therapies aimed at treating chronic inflammatory diseases. The company is leveraging its expertise to build a pipeline of proprietary small molecules and antibodies. Using functional T cell assays, they screen and discover potent product candidates that target validated immune pathways.

The company’s leading product candidate is rademikibart, previously known as CBP-201. This antibody is designed to target the interleukin-4 receptor alpha (IL-4Rα) and is currently under development for treating atopic dermatitis and asthma. The company hopes that rademikibart will provide a new therapeutic option for patients suffering from these chronic conditions.

In addition to rademikibart, Connect Biopharma is also developing another promising candidate, icanbelimod, formerly known as CBP-307. Icanbelimod is a modulator of S1P1 T cell receptors and is being developed for the treatment of ulcerative colitis (UC), a chronic inflammatory bowel disease. This development highlights the company's commitment to addressing a broad range of chronic inflammatory conditions through innovative therapeutic approaches.

Connect Biopharma’s efforts are centered on improving the lives of millions of individuals affected by chronic inflammatory diseases globally. By utilizing advanced research in T cell biology, the company aims to create effective treatments that can significantly impact patient care and quality of life.

The upcoming investor meetings at the Leerink Partners Forum represent a crucial opportunity for Connect Biopharma to share its progress and future plans with potential investors. Such engagements are vital for the company to secure the necessary support and resources to continue its groundbreaking work in biopharmaceuticals.

Overall, Connect Biopharma is positioning itself as a leading player in the biopharmaceutical industry, with a strong focus on developing therapies that address unmet medical needs in chronic inflammatory diseases. By advancing its pipeline of innovative products, the company demonstrates its dedication to delivering meaningful health solutions to patients worldwide.